Last reviewed · How we verify
LY2189102
At a glance
| Generic name | LY2189102 |
|---|---|
| Sponsor | Eli Lilly and Company |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- A Study to Evaluate the Efficacy and Safety of AVTX-009 in Patients With Moderate to Severe Hidradenitis Suppurativa (PHASE2)
- A Study of LY2189102 in Patients With Type 2 Diabetes (PHASE2)
- A Safety and Pharmacokinetics Study in Participants With Rheumatoid Arthritis (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- LY2189102 CI brief — competitive landscape report
- LY2189102 updates RSS · CI watch RSS
- Eli Lilly and Company portfolio CI